Oruka Therapeutics Inc.

09/18/2025 | Press release | Distributed by Public on 09/18/2025 09:13

September 18, 2025 - EADV 2025 - EVERLAST-A Phase 2a Study Design

Oruka Therapeutics Inc. published this content on September 18, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on September 18, 2025 at 15:13 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]